Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in SLE: Understanding of Long-term Responses and the Impact of B Cell Depletion on T Cells
NCT01702038Phase 2Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in systemic lupus erythematosus (SLE), sponsored by National Institute of Allergy and Infectious Diseases. Planned start Sep 2009; status: withdrawn.
02
Drugs
rituximab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT01702038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01702038.